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Abstract: Barrett’s esophagus is a metaplastic alteration of the normal esophageal epithelium 
that is detected on endoscopic examination and pathologically conﬁ  rmed by the presence of 
intestinal metaplasia on biopsy. Its major signiﬁ  cance is as a predisposing factor for esophageal 
adenocarcinoma, which carries a high mortality rate and a rapidly growing incidence in the 
United States. Detection of Barrett’s esophagus allows for endoscopic surveillance in order to 
detect the potential development of dysplasia and early cancer before symptoms develop, and 
thereby signiﬁ  cantly increases treatment options and may lower mortality from esophageal 
adenocarcinoma. Much current work in the ﬁ  eld is aimed at reducing the risk of progression 
from Barrett’s esophagus to cancer, and in the identiﬁ  cation of biomarkers that may predict 
progression towards cancer. Barrett’s esophagus is present in 10%–20% of patients with gas-
troesophageal reﬂ  ux disease (GERD) and has also been detected in patients who deny classic 
GERD symptoms and are undergoing endoscopy for other indications. We used an evidence-
based approach to describe treatment options for patients with Barrett’s esophagus.
Keywords: Barrett’s esophagus, esophageal adenocarcinoma, evidence-based approach, 
endoscopic surveillance
Introduction
Esophageal adenocarcinoma carries a grave prognosis, with a relative 3-year survival 
rate of only 20% in the United States from 1995–1998 (Polednak 2003). According to 
data from the Surveillance, Epidemiology, and End Results program (SEER) database, 
the incidence of esophageal carcinoma is rising more rapidly than any other form of 
cancer, with a six-fold increase from 1975 to 2001 (Devesa et al 1998; Brown and 
Devesa 2002; Pera et al 2005; Pohl and Welch 2005). As a predisposing condition 
to esophageal adenocarcinoma, gastro-esophageal reﬂ  ux disease (GERD) is one of 
the most common medical conditions in the US, causing symptoms in up to 40% of 
individuals living in Western populations every month and 7% per week (Gallup 
Organization 1988; Moayyedi and Axon 2005).
The link between GERD and esophageal adenocarcinoma is Barrett’s esophagus 
(BE), a condition characterized by metaplastic changes in the esophageal epithelium. 
In this review, we summarize the current knowledge regarding the epidemiology, 
pathophysiology, and treatment of patients with this diagnosis.
Methods
We performed a review of the literature published in English from 1970 to 2006, using 
PUBMED/MEDLINE to obtain references for topics addressed herein. Abstracts 
corresponding to potentially relevant titles were reviewed, and relevant articles were 
retrieved to evaluate data and content.
For the prevention and treatment sections, an evidence-based approach to the 
literature was used, employing a standard scoring system (Dent et al 1999). Evidence Therapeutics and Clinical Risk Management 2007:3(6) 1036
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was placed in one of ﬁ  ve categories. All references were 
examined independently by the two authors, who assigned 
a categorical rating to each evidence-based treatment state-
ment. If there was a difference of opinion, a consensus was 
reached. Rating categories were deﬁ  ned as follows:
• Evidence  rated  Category A was obtained from random-
ized clinical trials.
• Evidence  rated  Category B was from cohort or case-
control studies.
• Evidence  rated  Category C was based on case reports, or 
ﬂ  awed clinical trials.
• Evidence  rated  Category D was limited to the clinical 
experience of the supervising author.
•  Where evidence was insufﬁ  cient to form an opinion, it 
was rated Category E.
Incidence
Original retrospective data suggested an incidence of BE 
amongst patients with reﬂ  ux symptoms between 8% and 
20%, but this estimate may have been inﬂ  uenced by the pres-
ence of selection bias (Cameron 1997). For example, in two 
recent prospective studies, patients presenting for colonos-
copy who agreed to upper endoscopy for study purposes were 
examined. In the ﬁ  rst study, approximately 8% of subjects 
who reported any history of heartburn had endoscopic ﬁ  nd-
ings of Barrett’s esophagus, compared to 6% of those who 
did not report such GERD symptoms (Rex et al 2003). In the 
second study, a high overall rate of BE was seen, but again 
absence of reﬂ  ux symptoms did not dramatically lower the 
risk of ﬁ  nding metaplasia; 20% of patients with symptoms, 
compared to 15% of asymptomatic patients, were found to 
have BE (Ward et al 2006). In this study, males were twice as 
likely as females to have BE (22% vs 11%), consistent with 
prior studies and the 2:1 ratio found by recent meta-analysis 
of the gender ratio for Barrett’s esophagus (Cook et al 2005). 
Taken together, these newer studies conﬁ  rm an 8%–20% 
rate of BE amongst patients with reﬂ  ux symptoms, similar 
to the prior retrospective work. In addition, they suggest an 
equally high rate of BE in the general population without 
GERD symptoms.
Our own work in patients presenting for screening sig-
moidoscopy at a Veteran’s Hospital, who agreed to upper 
endoscopy for study purposes, found that 25% of patients 
without signiﬁ  cant reﬂ  ux symptoms had BE detected (Gerson 
et al 2002). The higher rate of BE in this study could have 
been inﬂ  uenced by the predominantly male population in 
the study, the fact that patients screened were all at least 
50 years of age, and the inclusion of patients who reported 
having GERD symptoms once a month or less. However, the 
majority (51%) of the patients denied the presence of GERD 
symptoms in their lifetimes.
Using a different approach to examine the incidence of 
BE in the general population, one study prospectively evalu-
ated unselected autopsy materials from patients at the Mayo 
Clinic. Only about 1% of 733 deceased patients evaluated 
by autopsy were found to have Barrett’s esophagus; when 
adjusted for age and gender, this may suggest a much lower 
incidence of BE in the general population of  0.4% (Cameron 
et al 1990; Cameron 1997). Despite this low percentage, 5 out 
of the 7 autopsy cases of BE did not have previously known 
disease, and the authors were able to demonstrate that the 
rate of BE determined by autopsy is much greater than the 
rate of known BE cases in the local community.
Cases of BE can be further divided by the length of BE 
segment. Short-segment disease is generally deﬁ  ned as 
intestinal metaplasia of the distal esophagus that is less than 
3 cm in length, while long-segment BE refers to segments 
measuring 3 cm or greater. Interestingly, short-segment 
disease appears to be at least 3 times more common than 
long-segment disease (Hirota et al 1999; Csendes et al 
2003; Hanna et al 2006), and longer segment length has 
been correlated with greater acid exposure (Fass et al 2001). 
However, once BE develops its length does not generally 
change, so that short-segment BE normally remains short 
even in the context of ongoing esophageal exposure to acid 
(Cameron and Lomboy 1992). The rate of dysplasia has been 
directly correlated with segment length (Hirota et al 1999; 
Csendes et al 2003). Because both long and short segment 
disease are associated with development of dysplasia and 
adenocarcinoma (Sharma et al 1997a), both forms of BE 
are treated similarly with regards to endoscopic surveillance 
and treatment.
Misdiagnosis of BE can occur for a variety of reasons. 
The diagnosis of BE is dependent upon the identiﬁ  cation of 
any length of distal esophageal columnar-lined tissue contain-
ing goblet cells in biopsy specimens. If biopsies are obtained 
in the setting of a normal esophagogastric junction (EGJ) and 
demonstrate intestinal metaplasia, then the patient has intes-
tinal metaplasia of the GE junction (SIM-EGJ), a condition 
found in 10%–15% of patients undergoing upper endoscopy 
for any indication (Hirota et al 1999) that is more common in 
patients infected with Helicobacter pylori. SIM-EGJ is not an 
indication for entry into an endoscopic surveillance program. 
The second reason for misdiagnosis is based on the landmark 
used for determining the location of the EGJ. Based on the 
Prague C and M Criteria for Barrett’s esophagus, the upper Therapeutics and Clinical Risk Management 2007:3(6) 1037
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end of the gastric folds is used in order to deﬁ  ne the location 
of the EGJ. (Armstrong 2004) It is important to identify the 
EGJ correctly since most cases of BE are of short length. 
Correct identiﬁ  cation of the gastric folds requires that air 
must be properly deﬂ  ated during endoscopy and other fac-
tors, such as respiratory movements and cardiac pulsations, 
be taken into consideration (Amano et al 2006).
Etiology and pathophysiology
GERD is accepted as the primary etiologic factor for BE, 
which is in turn the major predisposing condition for 
esophageal adenocarcinoma. From a pathophysiologic 
perspective, BE is thought to be the result of esophageal 
epithelial response to injury. Acid-induced injury to the 
native squamous cell epithelium of the esophagus leads to 
epithelial repair; eventually, but only in some cases, colum-
nar epithelium can replace the native epithelium (Spechler 
2002), offering greater tolerance to low pH, but also a ten-
dency towards dysplastic change predisposing to esophageal 
adenocarcinoma. A summary of this model of progression 
from normal esophagus to BE to esophageal cancer is shown 
in Figure 1, including endoscopic and histologic appearance 
of the esophageal mucosa during this progression.
In a canine model of acid reﬂ  ux disease, dogs with 
induced GERD were studied for regeneration of injured 
esophageal epithelium; the majority (7/10) of the dogs devel-
oped columnar epithelium in place of the normal squamous 
epithelium (Li et al 1994, Gillen et al 1988). Of note, in the 
canine model, experiments demonstrated that metaplastic 
changes in esophageal epithelium, as opposed to proximal 
migration of columnar cells from the gastric cardia, were 
responsible for the changes observed (Gillen et al 1988). 
Indeed, the replacement of the normal epithelium of the 
distal esophagus with columnar epithelium is considered a 
metaplastic process, and the characteristic columnar histol-
ogy of the altered tissue is described as specialized intestinal 
metaplasia (as it typically also contains intestinal crypts and 
goblet cells).
Interestingly, while duration of GERD symptoms is 
clearly a risk factor both for development of BE (Eisen et al 
1997; Lieberman et al 1997) and greater length of BE seg-
ment (Fass et al 2001), the extent of BE does not typically 
expand over time; that is, the length of the Barrett’s seg-
ment of distal esophagus is established over a relatively short 
period of time (months), and changes little over subsequent 
years (Cameron and Lomboy 1992). Furthermore, use of 
proton pump inhibitors (PPIs) to prevent acid reﬂ  ux does 
not result in signiﬁ  cant reduction in the length of existent 
Barrett’s esophagus (Sharma et al 1997b).
Additional factors that appear to be risk factors for the 
presence of BE include obesity, the presence of hiatal hernia, 
and interestingly, the absence of Heliobacter pylori infection. 
Speculation is that all of these factors contribute to BE by 
increasing the risk and severity of acid reﬂ  ux. Hiatal hernia 
distorts the anatomy the normally protects against reﬂ  ux by 
reducing pressure at the lower esophageal sphincter, creating 
an acidic hernia sac between the diaphragm and the esopha-
gus, and decreasing the efﬁ  cacy of peristalsis (Gordon et al 
2004). One recent study shows that of 50 patients with GERD 
who developed BE, 63% had the ﬁ  nding of a hiatal hernia 
(Westhoff et al 2005), and another study demonstrated that 
longer length of hiatal hernia correlated with longer segment 
of BE (Dickman et al 2005).
GERD, BE and esophageal adenocarcinoma have all been 
associated with the presence of obesity. The relationship 
between GERD and obesity is thought to be in part due to 
A. Esophagitis B. Barrett’s esophagus C. Esophageal cancer
Figure 1 Progression of disease, demonstrating changes observed as esophagitis (A) undergoes metaplasia, leading to salmon-colored mucosal changes in the distal esopha-
gus characteristic of Barrett’s esophagus (B) Dysplasia develops (C).Therapeutics and Clinical Risk Management 2007:3(6) 1038
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increased gastroesophageal sphincter gradient (Mercer et al 
1987), intra-abdominal pressure (El-Serag et al 2006b), and 
increased incidence of hiatal hernia in obesity (Pandolﬁ  no 
et al 2006). A recent retrospective case-control study showed 
a strong direct relationship between mean visceral adipose 
tissue and BE when comparing patients with and without 
BE who had undergone both endoscopy and an abdominal 
CT scan at a large Veterans’ Hospital (El-Serag et al 2005). 
A similar correlation between body mass index (BMI) and 
BE was found in another study, with an adjusted odds ratio of 
1.35 for each ﬁ  ve-point increase in BMI (Stein et al 2005).
Heliobacter pylori, in contrast to obesity and hiatal 
hernia, may affect the risk of BE by physiologic rather 
than anatomic means; H. pylori can decrease gastric acidity 
through activity of urease (Sharma and Vakil 2003). The 
fact that H. pylori may be protective against BE is a contrast 
to its well established status as a risk factor for peptic ulcer 
disease (PUD) and gastritis, and indeed eradication of H. 
pylori for PUD may increase risk of BE. One strain of H. 
pylori containing the virulence factor cytotoxin-associated 
gene (cagA) may be particularly protective. In patients with 
the cagA+ strains of H. pylori, one study of 153 patients 
who had undergone endoscopy found that patients with BE 
and particularly those with BE and dysplasia or cancer were 
much less likely to be infected than controls; 42% control 
patients were positive for this strain of H. pylori, as opposed 
to 13% of patients with BE and 0% of patients with BE and 
dysplasia and cancer (Vicari et al 1998). In a similar study 
of 251 patients undergoing endoscopy, cagA+ H. pylori 
was present in 44% of 25 controls, 36% of 36 patients with 
GERD, 20% of 10 patients with short-segment BE, and 0% 
of 18 patients with long-segment BE (Vaezi et al 2000), 
resulting in an odds ratio of 0.27 for BE patients infected 
with H. pylori compared to patients with reﬂ  ux but no BE. In 
addition to this inverse correlation with BE, studies have also 
shown a protective effect of H. pylori on the development of 
esophageal adenocarcinoma (de Martel et al 2005). Until the 
association between BE and its complications with negative 
H. pylori status is further clariﬁ  ed, it may be prudent to avoid 
H. pylori eradication in patients whose predominant problem 
is attributed to GERD rather than gastritis or PUD.
The risk factors for BE highlight again the role of reﬂ  ux 
in its pathogenesis. Given the response to injury model of 
BE, reﬂ  ux-associated erosive esophagitis (EE) is considered 
a likely intermediate step on the path towards development 
of metaplasia. However, to date, no clear data exist to vali-
date that all patients with BE have had prior erosive disease. 
Recently, a study of 172 Veterans with reﬂ  ux symptoms 
demonstrated that 12% of patients with EE on endoscopy 
(but no evidence of BE) were found to have BE on repeat 
endoscopy 8–16 weeks later, after completing PPI therapy 
for EE (Hanna et al 2006). The ﬁ  nding of BE development in 
some of these patients may suggest that BE was present but 
not detected in some patients with EE on initial evaluation, 
due to the clinical appearance of erosive disease masking the 
presence of metaplasia. In some cases, intestinal metaplasia 
can be detected if biopsies are obtained in the setting of 
erosive disease, however in other cases it may be missed due 
to sampling error because of the limited visibility. However, 
BE should become apparent due to healing of esophagitis 
after PPI therapy. Alternatively, BE may have developed 
in these patients during treatment with PPI, with columnar 
epithelium developing as part of the healing process. Thus it 
is not clear whether this study addresses a temporal progres-
sion from EE to BE, or a limit of current detection of BE in 
the setting of active EE.
The relationships among GERD, BE, and esophageal ade-
nocarcinoma are clearly established. Duration and severity 
of GERD symptoms increases risk not only for BE, but also 
for esophageal adenocarcinoma; in fact, patients with severe 
and prolonged symptoms of GERD have an odds ratio of 
43.5 for development of esophageal adenocarcinoma com-
pared with patient who did not report any recurrent GERD 
symptoms (Lagergren et al 1999). However, the same study 
also showed that 40% of patients with esophageal adeno-
carcinoma denied having had GERD symptoms, perhaps 
reﬂ  ecting the signiﬁ  cant portion of BE patients who do not 
report symptoms of reﬂ  ux.
Prevention and screening
Treatment of GERD patients with PPIs 
to prevent development of BE
If acid-induced epithelial injury leads to Barrett’s metaplasia, 
it follows that acid suppression may prevent such metaplasia. 
Indeed, amongst patients diagnosed with BE, those who had 
been treated pharmacologically for acid suppression prior 
to diagnosis had signiﬁ  cantly shorter length of disease. 
Patients who had not received such treatment had an aver-
age BE segment length of 4.8 cm, as opposed to 3.2 cm for 
those treated with PPI therapy prior to diagnosis (p   0.001) 
(El-Serag et al 2004).
Recommendation
No data exist to demonstrate prevention of BE using PPI 
therapy. However, such treatment is theoretically compel-
ling, and there are the data to suggest shorter segments of Therapeutics and Clinical Risk Management 2007:3(6) 1039
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BE amongst PPI users. Therefore usage of PPIs in patients 
with reﬂ  ux is recommended for control of reﬂ  ux symptoms 
and may be associated with the increasing prevalence of 
short-segment BE. Evidence rating: Category B.
Use of non-steroidal anti-inﬂ  ammatory 
drugs (NSAIDs) to prevent BE
There has been interest for some time regarding the usage of 
non-steroidal anti-inﬂ  ammatory agents (NSAIDs) and COX-2 
inhibitors in order to reduce esophageal inﬂ  ammation and 
proneoplastic stimuli (Kaur et al 2002; Altorki et al 2004). 
Such agents are speculated to prevent either development 
of metaplasia or progression of metaplasia to dysplasia and 
cancer. A recent case-control study of patients in Ireland 
demonstrated that patients who reported use of aspirin or 
other NSAIDs were less likely to develop BE, with an odds 
ratio of 0.53 and 0.40 respectively, a difference which was 
statistically signiﬁ  cant but potentially subject to selection or 
recall bias (Anderson et al 2006). This result is consistent 
with work in animals showing reduced incidence of esopha-
geal columnar-lined epithelium in a rat model of acid reﬂ  ux, 
when those rats were treated with a COX-2 inhibitor (Oyama 
et al 2005). Furthermore, data from case-control studies and 
a prospective cohort study suggest that aspirin and other 
NSAIDs reduce the risk of development of esophageal cancer 
(Farrow et al 1998; Jolly et al 2002). A prospective study of 
the duration, frequency and recency of NSAID usage and 
the risk of esophageal carcinoma in the Seattle BE cohort of 
350 patients revealed that the 5-year cumulative incidence 
of esophageal adenocarcinoma was 14% for never users, 
10% for former users, and 7% for current NSAID users. 
Compared to never users, current NSAID users had less 
aneuploidy (n = 35, hazard ratio of 0.25) and tetraploidy 
(n = 45, HR = 0.44) (Vaughan et al 2006).
Recommendation
Case control studies suggest a protective effect of NSAIDs 
for the development of BE and the progression to dyspla-
sia and/or carcinoma. The potential beneﬁ  t from usage of 
NSAIDs in patients with BE must be weighed against their 
signiﬁ  cant potential for adverse effects (including esophageal 
injury). Evidence rating: Category B.
Screening for development of BE 
in GERD patients
The association between longstanding GERD symptoms 
and development of BE has historically been strong (Eisen 
et al 1997), with one study showing an odds ratio of 3.0 
and 6.4, respectively, for development of BE in patients 
having GERD symptoms for 1–5 years versus greater than 
10 years (Lieberman et al 1997). Males with long-stand-
ing reﬂ  ux symptoms appear to be at the greatest risk for 
the development of BE (Gerson et al 2001). Based on the 
prior literature, endoscopic screening for BE in reﬂ  ux 
patients who report  1 year of GERD symptoms is rec-
ommended.
There is now a growing body of evidence that there is an 
equally high rate of BE amongst patients who do not report 
signiﬁ  cant or longstanding GERD symptoms (but who likely 
have asymptomatic reﬂ  ux). The signiﬁ  cance of this “asymp-
tomatic” cohort is substantiated by the fact that a signiﬁ  cant 
portion of patients who develop esophageal adenocarcinoma 
have no history of GERD symptoms; in one key study, 76 out 
of 189 patients (40%) with this form of cancer had no history 
of symptomatic GERD (Lagergren et al 1999). This is similar 
to the 43% of patients with no history of GERD symptoms 
found to have esophageal carcinoma in a 1984 study, in which 
all 26 patients evaluated had BE with dysplasia surrounding 
the cancer at time of diagnosis (Smith et al 1984). Remark-
ably, in a systematic review of the literature, only about 5% 
of patients with esophageal adenocarcinoma had a known 
history of BE prior to diagnosis of cancer (Dulai et al 2002), 
reﬂ  ecting serious limitations to our current ability to catch 
premalignant BE by screening. As discussed in the section 
on treatment, premalignant diagnosis of BE substantially 
improves survival of subsequent cancer, as cancer is caught 
early due to surveillance measures.
Recommendation
Patients with longstanding ( 1 year) GERD symptoms 
should be screened for development of BE, dysplasia, and 
early esophageal adenocarcinoma. Additionally, all patients 
found to have erosive esophagitis should have follow-up 
endoscopy after treatment both to determine clearance of 
esophagitis and absence of BE. If the development of esopha-
geal cancer can be prevented by endoscopic detection of BE, 
then future studies should focus on the identiﬁ  cation of who 
should undergo endoscopic screening regardless of the pres-
ence of classic reﬂ  ux symptoms. As molecular markers for 
risk of malignant transformation are reﬁ  ned (see below), it 
may become clinically beneﬁ  cial and cost-effective to screen 
a larger segment of the general population for BE. Currently, 
however, insufﬁ  cient data exist to recommend screening in 
the general population (Gerson and Triadaﬁ  lopoulos 2002), 
since the risk of developing esophageal cancer remains 
remains low overall. Evidence rating: Category B.Therapeutics and Clinical Risk Management 2007:3(6) 1040
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Treatment
Once Barrett’s esophagus has developed, treatment is 
primarily directed at prevention of progression to esopha-
geal adenocarcinoma, as well as at control of GERD 
symptoms. Cancer prevention is currently achieved primar-
ily by monitoring for progression to dysplasia, and then 
consideration of action to remove the dysplastic tissue before 
it progresses to malignancy. Treatment to reduce acidity of 
stomach content is employed not to treat the BE itself, but 
to treat GERD symptoms; its unclear role in prevention of 
cancer is also discussed below.
Role of PPI therapy in patients with BE
PPI use does not typically result in reduction of BE length 
once it has formed (Sharma et al 1997b), although very 
aggressive acid suppression therapy may yield slight 
reduction in length of metaplastic tissue (Peters et al 
1999). PPI therapy may also lead to islands within seg-
ments of Barrett’s that have macroscopic appearance of 
squamous epithelium (Sharma et al 1998). These islands 
are of unclear significance, and about a third of them 
have the pathological appearance of specialized intestinal 
metaplasia despite reversal of macroscopic appearance 
(Sharma et al 1998).
A problem currently under debate in the treatment of 
acid reﬂ  ux is that of inadequate pH neutralization. Available 
data demonstrate that even twice-daily PPI administration 
allows for periods of signiﬁ  cant nocturnal gastric acidity with 
pH   4.0 in the majority of patients, despite good control 
of symptoms in most (Katz et al 1998). In the same study, 
half of all Barrett’s patients also had abnormal percentage of 
the time that the esophageal pH readings were  4.0 despite 
the PPI therapy.
Our work with various PPIs conﬁ  rms the frequent occur-
rence of inadequate pH control. We have previously shown 
that patients with BE are less likely to achieve adequate 
esophageal pH control on PPIs compared to patients with 
GERD alone (50% vs 58%), and the degree of acid reﬂ  ux 
in treated BE patients was more pathologic compared to 
the GERD cohort (Gerson et al 2004a). Second, control of 
reﬂ  ux symptoms on PPIs does not indicate adequate control 
of acid reﬂ  ux into the esophagus: 62% of BE patients treated 
with esomeprazole had pathologic esophageal acidity, par-
ticularly at night, despite control of symptoms (Yeh et al 
2003). Finally, our study of BE patients using three different 
PPIs showed that intragastric pH was  4.0 fully 46% of the 
time for patients taking omeprazole, 71% of the time for 
patients on lansoprazole, and 51% of the time for patients 
on rabeprazole, correlating with a high rate of pathologic 
esophageal pH (Gerson et al 2005).
Experimental evidence based on metaplastic tissue 
collected from BE patients and studied in tissue culture 
demonstrates that pulsatile exposure to low pH leads to 
hyperproliferation relative to growth at neutral pH, whereas 
continuous exposure to acidic ﬂ  uid actually suppresses 
proliferation (Fitzgerald et al 1996). While pulsatile expo-
sure of esophageal tissue to acidic ﬂ  uid is characteristic of 
GERD, the effect of more limited (nocturnal) pulsatile acid 
exposure in patients with specialized intestinal metaplasia 
who manifest inadequate acid suppression on PPIs is not 
known. One study of 39 patients with BE found that after 
six months on PPIs, biopsy specimens showed a decrease 
in the expression of a proliferation marker (PCNA) and and 
increase in expression of a differentiation marker (villin) in 
patients who had good control of esophageal pH but not in 
those found to have persistent acid reﬂ  ux (Ouatu-Lascar et al 
1999). This suggests that control of acid reﬂ  ux may, indeed, 
interfere with development of dysplasia. Additionally, while 
clinical data are limited, results from an observations trial at 
a Veterans’ hospital has supported the idea that use of PPIs 
after BE diagnosis may signiﬁ  cantly lower risk of progressing 
to dysplasia, ﬁ  nding a hazard ratio of only 0.25 compared 
with those who did not receive PPIs (El-Serag et al 2004).
Another interesting ﬁ  nding is that patients with limited 
control of acid reﬂ  ux on ranitidine showed a signiﬁ  cant 
increase in an index of proliferation of metaplastic tissue 
biopsies taken over two years of treatment, whereas patients 
with much tighter control on omeprazole showed no change 
in proliferation (Peters et al 2000). This was not a controlled 
study, and thus it is unclear how changes in proliferation 
on ranitidine compare to the natural course of the disease 
towards dysplasia.
Recommendation
Limited clinical data suggests that PPI might prevent progres-
sion of metaplastic tissue towards dysplasia and/or cancer. 
Use of H2 blockers is associated with inferior control of 
reﬂ  ux symptoms and intra-esophageal pH, and is not cur-
rently recommended in BE. Evidence rating: Category B.
Surgical treatment of reﬂ  ux in BE patients
Currently available evidence suggests that surgery targeted at 
reducing reﬂ  ux (such as fundoplication) may not signiﬁ  cantly 
reduce risk of progression from BE to esophageal cancer. 
A 2003 meta-analysis of 34 studies in patients with BE involv-
ing surgery to reduce reﬂ  ux (4678 patient years) compared Therapeutics and Clinical Risk Management 2007:3(6) 1041
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with medical therapy (4906 patient years) found no statistically 
signiﬁ  cant difference in rates of progression to cancer (Corey 
et al 2003). These rates were 3.8 cancers per 1000 patient years 
in the surgery group vs. 5.3 cancers per 1000 patient years 
in the medical group (p = 0.3), with the rate of cancer in the 
medical group dropping to 4.2 per 1000 patient years when 
only considering studies from 1996–2001 (likely reﬂ  ecting 
improvement in pharmacotherapy). One limitation of these 
data is that they are derived from nonrandomized cohort stud-
ies and allow for signiﬁ  cant selection bias, such that patients 
with more signiﬁ  cant symptoms may have been more likely 
to choose surgery. Long-term follow-up from a randomized 
controlled trial of patients with GERD also concluded that 
surgical intervention (open Nissen fundoplication) was not 
signiﬁ  cantly better at preventing esophageal carcinoma than 
medical treatment, but the study was insufﬁ  ciently powered 
to detect modest differences (Spechler et al 2001).
Recommendation
Surgical intervention should not be employed to prevent 
reﬂ  ux in an effort to reduce risk of esophageal adenocarci-
noma in patients with BE, as it does not signiﬁ  cantly alter risk 
of malignant progression. Evidence rating: Category B.
Surveillance of BE for progression 
to dysplasia
While the metaplastic changes characteristic of Barrett’s 
esophagus represent a step towards development of cancer, 
the risk of progression to esophageal adenocarcinoma in 
patients with BE is only about 0.5% per year (Shaheen et al 
2000). Given this relatively low risk and the limits of cur-
rently available treatments, ablation or removal of BE is not 
currently advised unless there are additional risk factors for 
malignant transformation, such as the ﬁ  nding of dysplastic 
change on pathology. Patients shown to have high-grade 
dysplasia appear to have a variable subsequent 5-year risk of 
16%–60% for the development of malignancy (Weston et al 
2000; Reid et al 2000b; Schnell et al 2001). A prospective 
study of patients at a Veterans Affairs Hospital showed that 
only 16% of 75 patients with high-grade dysplasia developed 
cancer within a mean surveillance period of 7.3 years (Schnell 
et al 2001); of note, patients were excluded in this study if 
they developed cancer within the ﬁ  rst year of discovering 
high-grade dysplasia, as it was considered likely that such 
patients had cancer at time of initial diagnosis of high-grade 
dysplasia that was missed due to sampling error. The Seattle 
BE cohort experience of 76 patients with high-grade dys-
plasia found a 59% 5-year risk of cancer (Reid et al 2000b); 
when the 27 patients with incident HGD were analyzed, 
the incidence of cancer was 31% (Reid et al 2000b). Both 
of these studies lacked external pathologic conﬁ  rmation of 
high-grade dysplasia, likely overestimating the diagnosis 
of high-grade dysplasia. Even amongst pathologists highly 
experienced in gastrointestinal disease approximately 15% 
of the pathological specimens diagnosed as high-grade 
dysplasia may not be read as such by a second pathologist 
(inter-observer disagreement) (Reid et al 1988; Montgomery 
et al 2001). This fact highlights the need for obtaining con-
ﬁ  rmation from a second pathologist experienced in this area 
prior to conclusive diagnosis of high-grade dysplasia.
The diagnosis of low-grade dysplasia is of more limited 
utility than that of high-grade dysplasia, both because it 
is associated with a great deal of diagnostic imprecision 
(Skacel et al 2000; Montgomery et al 2001) and because its 
association with esophageal cancer is weaker (Skacel et al 
2000; Weston et al 2001). It is, however, associated with 
a signiﬁ  cant risk of progression to high-grade dysplasia 
(Skacel et al 2000; Weston et al 2001), which is increased 
when multiple pathologists agree with the diagnosis of 
low-grade dysplasia (Skacel et al 2000). Studies have 
demonstrated that up to 30% of patients with low grade 
dysplasia will show regression to normal tissue (Miros et al 
1991; Sharma et al 1997a).
Rational for surveillance, however, is not based on risk of 
development of cancer alone; rather, it is based on the obser-
vation that patients undergoing a surveillance regimen have 
signiﬁ  cantly greater survival rates when cancer is detected. 
In one study, 86% of 16 patients with esophageal adenocar-
cinoma found by surveillance of known Barrett’s were alive 
two years after cancer diagnosis, as opposed to 43% of 54 
patients who presented initially with cancer without prior 
known Barrett’s or surveillance (van Sandick et al 1998). In 
a similar study, 73% of cancer patients detected by surveil-
lance, as opposed to 12% of those discovered without surveil-
lance were alive 2 years after cancer diagnosis (Corley et al 
2002). While lead-time bias certainly accounts for some of 
this difference, actual survival is almost certainly prolonged, 
as nodal involvement is much less common in the surveil-
lance patients (van Sandick et al 1998) and additional data 
demonstrate that patients diagnosed by rigorous surveillance 
are much more likely to have resectable esophageal tumors 
than those initially presenting with cancer (Fitzgerald et al 
2001). A decision analysis demonstrated that screening and 
surveillance of BE is cost effective when patients found to 
have esophageal cancer who are not surgical candidates are 
offered endoscopic therapy (Gerson et al 2004b).Therapeutics and Clinical Risk Management 2007:3(6) 1042
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Recommendation
We currently advise utilization of a surveillance approach 
proposed by the American College of Gastroenterology in 
their Practice Guidelines for Barrett’s Esophagus updated in 
2002 (Sampliner 2002):
1.  No Dysplasia on two EGDs with biopsy → 3 year 
follow-up endoscopy
2.  Low-Grade Dysplasia on endoscopy → 1 year follow-up 
until no dysplasia
3.  High-Grade Dysplasia without cancer, conﬁ  rmed by 
experienced pathologist → 3 month follow-up or inter-
vention
Evidence rating: Category B.
Treatment of patients with high-grade 
dysplasia
A number of options are available to patients who have devel-
oped high-grade dysplasia. Some overlap exists between 
treatment options for high-grade dysplasia and those for 
esophageal adenocarcinoma, as well as for selected patients 
with lower-grade dysplastic changes. The three major 
approaches to high-grade dysplasia are observation with 
endoscopic surveillance, endoscopic ablation, and surgical 
intervention (principally esophagectomy).
The goal of observation with frequent surveillance is early 
detection of progression to cancer (Sampliner 2002). Reasons 
to manage a high grade dysplasia patient with observation 
include the highly variable risk (18%–60%) of progression to 
esophageal cancer, the very high morbidity and mortality of 
esophagectomy (up to 15% in low volume centers), and the 
risk of masking progression to cancer through ablation of the 
superﬁ  cial esophageal epithelium. As markers of progression 
towards malignancy (see below) become more established, 
patients under observation will be able to decide when to opt 
for more aggressive intervention based on molecular ﬁ  nd-
ings which correlate with cancer risk more accurately than 
dysplasia alone. Observation also allows patients to select 
more advanced treatments as they become available. The 
risk of observation, or course, is the inherent possibility of 
disease progression, the fact that intervention is less likely 
to succeed with more advanced disease (cancer), and the 
possibility that progression will be missed on surveillance 
(ie, sampling error). Prior studies have suggested that up to 
30% of patients with high grade dysplasia harbor esophageal 
cancer, but this ﬁ  gure was mainly derived from patients who 
were not enrolled in an intensive endoscopic surveillance pro-
gram (Edwards et al 1996; Heitmiller et al 1996; Incarbone 
et al 2002; Tseng et al 2003). In order to minimize the risk 
of missing progression to cancer, the recommended biopsy 
protocol in intensive, and involves four-quadrant biopsies at 
1 cm intervals, plus biopsies of any mucosal irregularities, 
every 3 months (Reid et al 2000a).
Endoscopic ablation, including argon plasma coagulation 
and photodynamic therapy, are better tolerated than esopha-
gectomy and offer the potential of complete obliteration of 
dysplastic epithelium (Johnston 2005). Major concerns with 
endoscopic ablation include the risk of stricture formation 
(Overholt et al 1999) and, importantly, the risk of subsqua-
mous metaplasia (Barham et al 1997). In the latter case, 
normal squamous epithelium grows to replace the ablated 
metaplastic/dysplastic epithelium, but islands of metaplastic 
cells survive underneath the normal-appearing epithelium. 
These can grow and progress to cancer without being vis-
ible on subsequent endoscopy, allowing for the much-feared 
possibility that advanced cancer can develop underneath the 
squamous epithelium.
While ablative techniques now offer an alternative, 
esophagectomy remains the deﬁ  nitive treatment in surgi-
cally ﬁ  t patients who have advanced high-grade dysplasia, 
especially when it is multifocal or associated with other 
mucosal irregularities, or in those who have progressed to 
early cancer. It offers the most reliable method of preventing 
progression to advanced or invasive cancer (Spechler 2002). 
However, it is an especially high-risk procedure, especially 
at low-volume institutions, where it carries a mortality rate 
as high as 15%, and an association with complications in 
two-thirds of patients; at tertiary care facilities with consider-
able experience in esophagectomy, the mortality risk drops 
to 3%–5% and the complication rate drops to just over half 
(Swisher et al 2000; van Lanschot et al 2001).
In patients with early esophageal cancer who are not 
operative candidates, endoscopic mucosal resection, photo-
dynamic therapy, and/or laser therapy have been shown to 
be reasonable treatment options associated with remission 
rates between 45% and 75%. (Overholt et al 1999; Ell et al 
2000; Van Laethem et al 2001; Wolfsen et al 2002). Local 
recurrence or metachronous cancer has been reported in up 
to 30% of patients but can be treated with endoscopic therapy 
with similar prognostic results.
Recommendations
Patients with high-grade dysplasia without multifocal 
features or mucosal irregularity can be followed using an 
intensive biopsy protocol (4-quadrant biopsies every 1 cm 
with 3 month follow-up), or may opt for more aggressive 
intervention. Surgical candidates with high-grade dysplasia Therapeutics and Clinical Risk Management 2007:3(6) 1043
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with concerning features, or early adenocarcinoma, should 
strongly consider esophagectomy as possible cure, balancing 
the risk of aggressive cancer with the considerable risk of 
surgery. Endoscopic ablation should be offered to patients 
who are not surgical candidates or who have serious reserva-
tions about surgery. Evidence rating: Category B.
Future possibilities in the treatment 
of patients with Barrett’s esophagus
Screening for Barrett’s esophagus in appropriately selected 
individuals is currently recommended because pathologic 
ﬁ  ndings can lead to surveillance methods that ultimately 
reduce the risk of mortality from cancer. An ideal screen-
ing tool would allow for simultaneous treatment of patients 
found to have risk-associated pathology, such as polyp 
removal during screening colonoscopy to prevent progres-
sion to colon cancer. At this point, no such option exists for 
Barrett’s esophagus, as no endoscopic treatment has been 
shown to safely eliminate or reduce the risk of progression 
to cancer. However, as techniques for endoscopic ablation 
become more advanced, it may become advantageous to 
eliminate Barrett’s mucosa early on, when only low-grade 
dysplasia or even metaplasia alone is present. Such an 
approach may not only reduce the risk of malignancy, but 
also eliminate the need for costly and tedious long-term 
surveillance.
Current techniques being used or explored for endo-
scopic ablation include photodynamic therapy, laser therapy, 
multipolar electrocoagulation, argon plasma coagulation, 
endoscopic mucosal resection, radiofrequency ablation, and 
cryotherapy (Johnston 2005). Preliminary work with radio-
frequency ablation, as an example, suggests that it may be 
capable of full-thickness epithelial ablation without injury 
to the submucosa or stricture formation (Ganz et al 2004; 
Johnston 2005). If further data demonstrate this technique 
is indeed capable ablating Barrett’s mucosa while mini-
mizing the risk of hidden subsquamous metaplasia and of 
complications such as strictures, it may allow for relatively 
safe elimination of metaplastic epithelium in patients with 
non-dysplastic Barrett’s esophagus; clinical trials in such 
patients are reportedly underway (Ganz et al 2004). Until 
such data exist, use of ablative technology in patients with-
out dysplasia is not indicated or appropriate outside of the 
realm of research.
Another area where progress is being made is that of 
biomarkers of transformation risk. Identiﬁ  cation of dysplasia 
or even high-grade dysplasia offers limited ability to risk-
stratify, as illustrated by the need for continued surveillance. 
Additional markers of transformation risk would thus be 
valuable tools in determining appropriate treatment. As an 
example, of 322 Barrett’s patients studied by a combina-
tion of histology and ﬂ  ow cytometric analysis for abnormal 
chromosomal number (aneuploidy or 4N), 247 had baseline 
histology that was either negative, indeﬁ  nite, or showed 
low-grade dysplasia (Reid et al 2000b). Of this subset, 215 
patient had neither aneuploidy nor 4N on ﬂ  ow cytometry; 
these patients had a 5-year cumulative cancer incidence of 
0%, as opposed to 28% of the 32 patients from the same 
group who were positive for either aneuploidy or 4N. Such 
numbers would clearly have implications for surveillance 
need. To date, a number of biomarkers have been identiﬁ  ed 
that can predict increased risk of progression of Barrett’s 
metaplasia to cancer by either ﬂ  ow cytometric analysis or 
gene chip technology (Reid et al 2003; Helm et al 2005; 
El-Serag et al 2006a); use of such markers may soon play a 
more routine role in surveillance of BE patients.
Recommendation
•  Ablation of non-dysplastic mucosa should occur in a clini-
cal research setting and cannot currently be recommended 
for all BE patients. Evidence rating: Category E.
•  Use of biomarkers is compelling but not yet standard-
ized. Flow cytometry is commercially available at the 
University of Washington and can be used to risk stratify 
patients with non-dysplastic BE as well as patients with 
high grade dysplasia. Evidence rating: Category B.
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